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Abstract
Purpose: Barrett’s esophagus (BE) is the sole precursor lesion of esophageal adenocarcinoma (EA) identified 
so far. The progression towards EA is estimated to affect 2 to 10% of BE patients, hence endoscopic surveillance 
of at-risk subjects is mandatory. Surveillance endoscopic procedures imply high cost, discomfort and risks for 
the patient, as well as the non-infrequent missing of small, focal lesions signaling progression to EA. Hence, it is 
important to search for new potential markers to better identify BE patients at risk of EA progression. The aim of this 
study was to produce a mouse model of BE, suitable for further molecular and genetic analyses.
Methods: Forty-four CD1 mice were operated upon by means of an esophago-jejunal anastomosis. Five CD1 
mice underwent a sham operation. The animals were sacrificed 10 months later and histological analysis was 
performed with Hematoxylin & Eosin and Alcian Blue staining.
Results: The overall postoperative mortality rate was 11%. Of the 39 operated animals 14% developed 
histologically detectable intestinal metaplasia in the lower esophagus. No histologically detectable lesions were 
shown in the sham group.
Conclusions: The mice model we propose could be applied because of its technical feasibility and acceptable 
mortality and can be used in transgenic mice too, in order to better understand molecular progression from BE to 
esophageal adenocarcinoma.
Keywords: Barrett’s esophagus; Mouse model; Intestinal metaplasia;
Histology 
Introduction 
Barrett’s Esophagus (BE) is a condition where the normal squamous 
epithelium of the esophagus is replaced by intestinal-type columnar 
epithelium. BE diagnosis is based on the presence of goblet cells of 
the intestinal type within columnar epithelium [1]. BE is thought to 
be a precursor lesion for esophageal adenocarcinoma (EA). Despite 
the relatively low progression rate of BE towards EA (EA is estimated 
to affect 2 to 10% of BE patients), endoscopic surveillance of at-
risk subjects is commonly applied. However, routinary endoscopic 
procedures must be applied with caution due to their cost, discomfort 
and risks for the patient, as well as for the non-infrequent missing of 
small, focal lesions signaling progression to EA. Considering that BE 
incidence has been sharply increasing in the last decades in Western 
countries [2] and that prognosis is still poor despite of recent advances 
in treatment [3], it is urgent to decipher the molecular mechanisms 
underlying BE progression towards EA, in order to improve its diagnosis 
and treatment. In particular, it is important to search for new potential 
markers to better identify BE patients at risk for progression to EA.
For this purpose, several animal models have been developed, 
however none of them is devoid of some weakness [4]. Indeed, the 
ideal animal model should encompass all the steps between BE and EA, 
also modelling the chronic inflammation which underlies any step of 
esophageal carcinogenesis [5]. Moreover, to better model human BE, 
genetic heterogeneity should be taken into account for the validation of 
the animal model [6]. The first animal model for BE was proposed by 
Bremner in 1970 and it was developed in dogs [7]. In the 90s, several 
animal models were proposed; however, most of them are rat models 
while only a few mouse models have been proposed more recently. 
Mice models are progressively substituting the rat, which is up to now 
the most used animal for BE models [8]. Indeed, a mouse model for 
EA, based on a surgical approach, has been recently described [9]. 
Mouse models usefulness in cancer research is due to several features, 
in particular mouse genome has been completely sequenced [10] and 
genetic manipulation is feasible.
The aim of this paper was that of developing and evaluating a 
surgical mouse model for BE, which could further apply to genetic and 
pharmacological studies.
Materials and Methods
BE induction in mice
Experiments in CD1 mice were performed at the Laboratory of 
Genetic Engineering for the Production of Animal Models (L.I.Ge.M.A) 
at the Animal House of the University of Florence. 44 three-week-
old CD1 mice were studied, represented by 39 operated according to 
the experimental model and 5 control (sham operated) mice at four 
different times. The characteristics of each series of mice are given in 
Table 1. Water and a standard chow were given until the day before 
surgery. Water was discontinued the morning of the operation. Mice 
were warmed by a hot lamp before and during the operation in order to 
prevent postoperative hypothermia. Anesthesia was performed by an 
intraperitoneal injection of Avertin (17 µl/g). All mice were operated 
on a small operating table and a 2-3 cm median laparotomy was 
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performed. After a wide divarication of both left liver lobe and left part 
of median lobe, esophagogastric junction was exposed. After sectioning 
of left gastric vessels, distal esophagus was sectioned after clamping in 
order to avoid esophageal retraction and the gastric side stitched with 
Goretex 8/0. Jejunum was prepared 5 cm after Treitz ligament and a 
small hole was performed in its wall by a 14 Fr intravenous cannula and 
an end to side esophago-jejunal anastomosis was performed either with 
Goretex 8/0 or silk 8/0 with the cut end of the esophagus. Abdominal 
wall was closed with nylon 4/0. As regard as the 5 control mices, a sham 
operation was performed. The same anesthesia protocol was applied 
as the other group and the operation consist in opening the abdomen 
and after an exploration excluding other concomitant pathologies, in 
closing it with nylon 4/0 as the other group. Liquid feeding was restored 
in the first post-operative day and solid feeding started the day after. All 
the animals which got sick or underwent a relevant weight loss were 
killed. In the control group mice a sham operation was performed. The 
experiment was ended after 10 months and mice were sacrificed. The 
study was conducted after the approval of the Ethical Committee, in 
accordance to the criteria outlined in the Guide for the Care and Use of 
Laboratory Animals.
Histological analysis
Samples were taken in the operating room of the animal facility 
immediately after the animal sacrifice. The entire stomach and 
esophagus were removed and were immediately fixed in formalin for 
at least 24 hours. Subsequently, samples were processed for paraffin 
embedding and 7 µm sections were obtained through a microtome 
and put on positive charged slides. Sections were then stained with 
Hematoxylin & Eosin following a standardised protocol and observed 
under a light microscope. The same samples were stained with Alcian 
Blue to detect goblet cells presence and an accurate examination of the 
sections was performed. 
Results
Data reported in this paper were obtained performing an esophago-
jejunal anastomosis in CD1 mice to establish a mouse model for BE.
Gastrojejunal anastomosis was performed with Goretex 8/0 in 20 
mice and with silk 8/0 in 19 mice in order to identify the best surgical 
technique. No significant difference was found neither for manual 
ability requested nor for results in terms of anastomotic leakage. A 
drawing showing the surgical procedure is reported in Figure 1A, while 
a representative picture showing the result of the surgical procedure is 
reported in Figure 1B.
Due to technical problems related to bleeding and/or anastomosis, the 
overall mortality rate was 11%. In particular, since in a first series animals 
suffered from hypothermia and anaesthesia problems, thereafter in addition 
to changes in the anaesthetic treatment, the temperature in the operation 
room was set at 30°C and animals were kept at the same temperature for 
2 hours after surgery. In the third series survival rate was lower; this was 
probably due to the lower mean weight of the animals. In the last group a 
thermophore set at 37°C was used, in addition to the previous adjustments 
and survival rate was significantly higher (Table 1). The higher survival rate 
in the last group of animals was probably due to different reasons: 1) the 
temperature was kept at higher 7 values to avoid hypothermia; 2) low doses 
of 2.5% Avertin were used for anaesthesia; 3) animals were fed with semi-
liquid food, obtained by homogenizing standard food with water, during 
the first three days after surgery.
Macroscopic evaluation, further corroborated by histological 
analysis of the samples, showed that animals belonging to the control 
group did not develop lesions, as witnessed by the presence of an intact 
Z-line to make the boundary between the squamous and gastric-type 
epithelia (Figure 2A). All the animals of the operated group showed 
the signs of gastric mucosal atrophy due to the esophago-jejunal 
A B
Figure 1: Surgical procedure. A) Drawing of the esophago-jejunal anastomosis performed in this study. B) Representative specimen from an operated animal, showing 
esophago-jejunal anastomosis
Group Number of Animals Mean Weight (Range)
Mortality Rate (%)
Intraoperative Perioperative After 1 week
I 5 28 g (26-30) 80 0 0
II 15 29 g (27-31) 20 26.7 26.7
III 12 24 g (21-26) 16.7 58.3 0
IV 12 30 g (28-34) 8.3 16.7 8.3
Table 1: Characteristics and mortality rates of the different groups of animals.
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anastomosis (Figure 2B). Moreover, 6 (14%) of the operated animals 
developed histologically detectable intestinal metaplasia in the lower 
esophagus. On the contrary, none of the controls animal developed 
atrophy or intestinal metaplasia in the lower esophagus.
When the presence of intestinal metaplasia was suspected, Alcian 
Blue staining was also performed, in order to detect goblet cells. The 
picture in Figure 3A shows the presence, at the gastroesophageal 
junction, of an area characterised by intestinal metaplasia. In Figure 3B 
a higher power microphotograph is reported, in which goblet cells can 
be better identified, stained in blue due to the presence of acid mucin 
which were selectively stained by Alcian Blue dye.
Discussion
In the past years, many progresses have been made in understanding 
the mechanisms of reflux esophageal injury which leads to BE and 
Barrett’s adenocarcinogenesis. However, human studies concerning 
the pathogenesis and relationship between the different steps of 
the carcinogenetic model obtain different results. It is well known 
that gastroesophageal reflux (GER) often causes peptic injury and 
inflammation of the esophageal squamous epi- thelium, a condition 
called reflux esophagitis. Esophagitis in most cases heals through the 
regeneration of squamous cells in the distal oesophagus. Conversely, 
in some patients esophagitis heals through a columnar-metaplastic 
process, which seems to represent a temptatively protective reaction 
to reflux injury since the metaplastic epithelium is more resistant 
to the noxious agents than the native tissue. In a minority of these 
cases intestinal-type columnar cells are represented; this condition 
is called Barrett’s esophagus (BE) and represents the most common 
esophageal pre- cancerous lesion. Therefore, the sequence of events-
reflux-esophagitis-intestinal metaplasia (BE)–dysplasia-invasive 
cancer is widely accepted as the main carcinogenetic pathway in the 
esophagus. However the mechanisms that underlie this progression 
need to be defined. Despite many molecules have been widely studied 
such as COX-2 [11], Herg1 [12], bcl-2 and bcl-xL [13], no conclusive 
studies are present literature. This is partly due to inter individual 
variability in humans and to the difficulties both in surveillance and 
in the interpretation of the endoscopic and histologic findings. For 
these reasons, the creation of a reproducible experimental model for BE 
(reviewed in [5]) is needed and can be useful to better understand the 
progression from BE to esophageal adenocarcinoma.
It is well known that, whereas humans might spontaneously develop 
BE, mice and rats do not, mainly because of differences in esophageal 
biology. For these reasons, surgery has been generally required for BE 
occurrence in rats and mice, although BE might be observed in animals 
treated with carcinogens, after esophagitis development [8]. Moreover, 
for the study of the molecular events involved in the carcinogenesis of 
Barrett’s carcinoma, a mouse model would be much more promising 
since most of the genetically altered animals are mice. However, no such 
mice models exist nowadays; it is probably due to the high mortality 
involved with the surgical procedure to create a mixed duodenogastric 
reflux and with the uncertain postoperative course of mice.
In a recent paper, a surgical approach similar to the one described 
in this paper was used [9]. However, several differences can be found 
between the two studies. First, mice included in the present study are 
3 weeks old while in the cited paper are 6-8 weeks old. Moreover some 
differences could be found in surgical technique too, especially in the 
materials used for sutures, and in the food administration. Finally we 
have a control group which is necessary to demonstrate the effect of 
duodenal reflux in the development of BE.
Conclusion
The aim of the study was to demonstrate that the model we 
proposed could be applied in mice because of a technical feasibility 
Figure 2: Hematoxylin&Eosin staining. A) Gastro-Esophageal junction of a control animal. Bar: 200 µm. B) Gastric atrophy in an operated mouse. Bar: 100 µm
Figure 3:  Alcian  Blue  staining.  A)  Intestinal  metaplasia  in  an  operated  mouse,  showing  the histological signs of BE. Bar: 200 µm. B) Higher magnification of 
the Alcian Blue-positive area. Bar: 50 µm
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and an acceptable mortality. In the literature many surgical procedure 
and the use of carcinogenic drugs have been reported. In spite of all 
the limitations of the present paper, our results show that this model 
can be used to study the development of reflux-induced esophagitis, 
BE and EA without using any drug. Therefore this model can be 
proposed also in engineered mice in order to better understand the 
role of duodenogastroesophageal reflux as well as the role of molecular 
markers in EA pathogenesis.
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